COMMUNIQUÉS West-GlobeNewswire

Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging
13/02/2026
- New Academic Data Supports Clinical and Commercial Value of Hybrid Imaging Platform- TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (“Conavi” or the “Company”), a leader in hybrid intravascular [...]
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
13/02/2026
PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on [...]
Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026
13/02/2026
ALK ( ALKB:DC / OMX: ALK B ) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, [...]
Nxera Pharma Proposes Changes to its Board of Directors
13/02/2026
Mr. Takeo Morooka nominated for appointment as new External Director Ms. Miwa Seki and Mr. Noriaki Nagai to retire from the Board of Directors Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“ [...]
EssilorLuxottica announces the launch of a share buyback program
13/02/2026
EssilorLuxottica announces the launch of a share buyback program Paris, France (13 February 2026 – 8:00am) – EssilorLuxottica announces the launch of a share buyback program, reflecting the Group’s confidence in its [...]
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions
13/02/2026
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions Paris, France (13 février 2026 – 8h00) – EssilorLuxottica annonce le lancement d’un programme de rachat d’actions qui traduit la confiance du [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
13/02/2026
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and [...]
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
13/02/2026
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended 1 Results favored Vanrafia across multiple timepoints, measures [...]
Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni grâce à un accord stratégique avec Smartway Pharmaceuticals
13/02/2026
L’accord avec CC Pharma renforce la croissance de Tilray au Royaume-Uni, consolidant sa distribution auprès des pharmacies et des hôpitaux NEW YORK et LONDRES, 13 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la [...]
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
13/02/2026
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
13/02/2026
BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
13/02/2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the [...]
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
13/02/2026
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum with Increased U.S. [...]
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
13/02/2026
Approval will broaden the NARCAN ® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE [...]
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 [...]
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
12/02/2026
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
BBOT to Participate in Upcoming Investor Healthcare Conferences
12/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Amwell® Announces Results for Fourth Quarter and Full Year 2025
12/02/2026
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the fourth [...]
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results
12/02/2026
MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results: Q4 2025 Q4 [...]

Pages